Poll Finds Majority Of Americans Want Restraints On Drug Prices
As the spiraling costs attract headlines, many people are looking to the government to rein in prescription drug prices, according to the Kaiser Family Foundation poll.
The independent source for health policy research, polling, and news.
1,221 - 1,240 of 1,309 Results
As the spiraling costs attract headlines, many people are looking to the government to rein in prescription drug prices, according to the Kaiser Family Foundation poll.
The research, published in JAMA Psychiatry, finds significant increases in the use of anti-depressants and depression diagnoses for women using hormonal forms of contraceptives, such as the pill.
Such medications account for more than a quarter of the state agency’s $2.1 billion in pharmacy costs.
Researchers examine the Food and Drug Administration’s “revolving door” regarding employees who worked on cancer and hematology drugs.
The number of prescriptions for Medicare beneficiaries is on the rise, too.
The initiative would prohibit California state agencies from paying more for a prescription drug than what the Department of Veterans Affairs pays. Both sides are deploying veterans’ sympathetic and trusted image to win over voters.
The FDA, reacting to lobbying by patients and families, has approved a drug for Duchenne muscular dystrophy, a rare and lethal disease.
Drug prices rise for a variety of reasons but opportunities for the government to control them is limited.
The flu vaccine is available for longer windows of time. Experts say to weigh convenience and science in deciding when to roll up your sleeve.
Patients living in the Northeast are more than twice as likely to get a powerful drug than those in the Midwest or South and African-Americans were 26 percent less likely to get the medicine, a study in the journal Neurology finds.
Based on an analysis of insurance company payments, emergency room visits and lab tests were responsible for much of the overall spending.
Consumers Union says Anthem Inc. and Blue Shield of California may be exploiting furor over prescription drug prices. State regulators are looking into the issue.
A closer look shows that industry lobbying was just one factor in EpiPen’s sales explosion.
A study in Health Affairs concludes that orphan drugs for rare diseases are not having a widespread or deep impact on health care spending.
Four years after a huge push to speed generics to market, the FDA has more than 4,000 generics waiting for approval.
As news that Mylan will make available a generic version of its own brand-name product, KHN answers key questions about how this development could affect consumers.
Older people are often given a huge number of medications, and many of them are unnecessary or even harmful.
A study in JAMA Internal Medicine suggests that patients known as the “worried well” are actually the highest utilizers of mental health care — and likely to receive antidepressants.
Researchers at Harvard University examined thousands of studies to determine why drug prices have climbed and what might be done about it.
The legislation would have required drug companies to notify the state and insurers about expensive new treatments or price hikes.
© 2026 KFF